Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low infectivity among asymptomatic patients with a positive severe acute respiratory coronavirus virus 2 (SARS-CoV-2) admission test at a tertiary care center, 2020-2022.
Tayyar R, Kiener MA, Liang JW, Contreras G, Rodriguez-Nava G, Zimmet AN, Contag CA, Srinivasan K, McIntyre K, Subramanian A, Shepard J, Tompkins LS, Pinsky BA, Salinas JL. Tayyar R, et al. Among authors: subramanian a. Infect Control Hosp Epidemiol. 2024 Feb;45(2):241-243. doi: 10.1017/ice.2023.210. Epub 2023 Sep 25. Infect Control Hosp Epidemiol. 2024. PMID: 37746805 Free PMC article.
SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA.
Hoffman SA, Costales C, Sahoo MK, Palanisamy S, Yamamoto F, Huang C, Verghese M, Solis DA, Sibai M, Subramanian A, Tompkins LS, Grant P, Shafer RW, Pinsky BA. Hoffman SA, et al. Among authors: subramanian a. Emerg Infect Dis. 2021;27(10):2720-2723. doi: 10.3201/eid2710.211461. Epub 2021 Jul 23. Emerg Infect Dis. 2021. PMID: 34296992 Free PMC article.
Use of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) strand-specific assay to evaluate for prolonged viral replication >20 days from illness onset.
Ferguson JD, Tayyar R, Contreras G, Kiener M, Zimmet AN, Contag CA, Rodriguez Nava G, Tompkins LS, Shepard J, Rosenthal A, Subramanian AK, Pinsky BA, Salinas JL. Ferguson JD, et al. Among authors: subramanian ak. Infect Control Hosp Epidemiol. 2023 Dec;44(12):2078-2080. doi: 10.1017/ice.2023.105. Epub 2023 Jun 29. Infect Control Hosp Epidemiol. 2023. PMID: 37381726
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.
Geng LN, Bonilla H, Hedlin H, Jacobson KB, Tian L, Jagannathan P, Yang PC, Subramanian AK, Liang JW, Shen S, Deng Y, Shaw BJ, Botzheim B, Desai M, Pathak D, Jazayeri Y, Thai D, O'Donnell A, Mohaptra S, Leang Z, Reynolds GZM, Brooks EF, Bhatt AS, Shafer RW, Miglis MG, Quach T, Tiwari A, Banerjee A, Lopez RN, De Jesus M, Charnas LR, Utz PJ, Singh U. Geng LN, et al. Among authors: subramanian ak. JAMA Intern Med. 2024 Sep 1;184(9):1024-1034. doi: 10.1001/jamainternmed.2024.2007. JAMA Intern Med. 2024. PMID: 38848477 Free PMC article. Clinical Trial.
Effectiveness of heterologous and homologous COVID-19 vaccination among immunocompromised individuals: a systematic literature review and meta-analysis.
Pardo I, Maezato AM, Callado GY, Gutfreund MC, Hsieh MK, Lin V, Kobayashi T, Salinas JL, Subramanian A, Edmond MB, Diekema DJ, Rizzo LV, Marra AR. Pardo I, et al. Among authors: subramanian a. Antimicrob Steward Healthc Epidemiol. 2024 Sep 26;4(1):e152. doi: 10.1017/ash.2024.369. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 39346662 Free PMC article.
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A; GS-US-540-5773 Investigators. Goldman JD, et al. Among authors: subramanian a. N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27. N Engl J Med. 2020. PMID: 32459919 Free PMC article. Clinical Trial.
SARS-CoV-2 Subgenomic RNA Kinetics in Longitudinal Clinical Samples.
Verma R, Kim E, Martínez-Colón GJ, Jagannathan P, Rustagi A, Parsonnet J, Bonilla H, Khosla C, Holubar M, Subramanian A, Singh U, Maldonado Y, Blish CA, Andrews JR. Verma R, et al. Among authors: subramanian a. Open Forum Infect Dis. 2021 Jun 11;8(7):ofab310. doi: 10.1093/ofid/ofab310. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34295944 Free PMC article.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939. JAMA. 2022. PMID: 35029629 Free PMC article. Clinical Trial.
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Holubar M, Subramanian A, Purington N, Hedlin H, Bunning B, Walter KS, Bonilla H, Boumis A, Chen M, Clinton K, Dewhurst L, Epstein C, Jagannathan P, Kaszynski RH, Panu L, Parsonnet J, Ponder EL, Quintero O, Sefton E, Singh U, Soberanis L, Truong H, Andrews JR, Desai M, Khosla C, Maldonado Y. Holubar M, et al. Among authors: subramanian a. Clin Infect Dis. 2022 Nov 30;75(11):1883-1892. doi: 10.1093/cid/ciac312. Clin Infect Dis. 2022. PMID: 35446944 Free PMC article. Clinical Trial.
1,245 results